# Enicepatide — dosage, half-life & reference guide | PepVault

Source: https://pepvault.app/peptides/enicepatide

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Metabolic & GLP-1](https://pepvault.app/peptides#metabolic)

# Enicepatide Dosage, half-life & reference guide

Also known as CT-388 · CT388 · RO7795068

Reviewed November 2026 1 study Evidence: Moderate [Published by PepVault](https://pepvault.app/guides/how-we-research)

A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened.

- **Studied range:** 4–24 mg starting dose 2 mg
- **How often:** Weekly
- **Half-life:** ~5.5 days
- **Evidence:** Moderate
- **Route:** SubQ injection

Studied in research — not a recommendation.

[Enicepatide dose guide](https://pepvault.app/lab/dosage/enicepatide)

## How it works.

Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, tirzepatide's pair, with a twist: it is built to trigger the receptors' main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell. The idea is that receptors stay on the surface and keep responding, so the effect lasts. Its half-life in people is about 5 to 6 days. Developed by Carmot Therapeutics and now Roche, in phase 3 since March 2026.

**Commonly reported:** In trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.

### Half-life & active level

The half-life of Enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).

Here's how a typical Enicepatide schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in [the half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator).

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track enicepatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Where Enicepatide works.

- ### Appetite & metabolism

  **In people.** At 48 weeks that group lost about 22.5% more weight than placebo, and nearly half lost at least 20% of their weight.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

## Week by week.

What to expect in the first 8 weeks

- **Onset:** Days–2 weeks
- **Peak effect:** 48 weeks (phase 2 endpoint, no plateau)
- **Duration:** Ongoing

1. Day 1–28 · 2 mg RCT

   ### Two milligrams, the first step

   You're on 2 mg, where the higher-dose groups in the phase 2 obesity trial began. Commonly reported: appetite dropping in the first days. In its trials, GI side effects were mostly mild to moderate and came with the step-ups.

   The science

   CT388-103 (NCT06525935; 469 adults with obesity or overweight without diabetes, 34 US sites): the 12, 16 and 24 mg groups started at 2 mg and stepped up through 4, 8, 12, 16 and 20 mg; the 4 and 8 mg groups started at 4 mg; all reached their top dose within 27 weeks, with delayed steps allowed for tolerability (Roche ADA 2026 poster). Most GI events were mild to moderate (Roche, Jan-27-2026).

   Sources

   - Roche (phase 2 obesity release) (2026)
   - Lingvay et al. (ADA poster) (2026)

   Updated Nov 2026
2. Day 29–112 · 8 mg RCT

   ### Through the middle steps

   You're at 8 mg, one of the doses the phase 2 trial also tested as a final dose. Commonly reported: a few queasy days after each step, then steadier appetite control. A slower step was allowed in the trial when side effects needed time to settle.

   The science

   CT388-103 tested final doses of 4, 8, 12, 16 and 24 mg (about 78 people each) against placebo, with a clear dose response for weight (Roche, Jan-27-2026; ADA 2026 poster). Delayed titration was allowed weekly from week 8 for the three highest-dose groups.

   Sources

   - Roche (phase 2 obesity release) (2026)
   - Lingvay et al. (ADA poster) (2026)

   Updated Nov 2026
3. Any day RCT

   ### What Enicepatide is built on

   A phase 1 trial with a published paper, and two 48-week phase 2 trials, one in obesity and one in type 2 diabetes, reported by Roche. Phase 3 began in March 2026. It is not approved anywhere.

   The science

   Discovery and phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405, sponsor Carmot): cAMP-biased at both receptors with minimal internalisation; weight loss in mice and monkeys; in people, single doses of 0.5 to 7.5 mg and four weekly doses of 5 to 12 mg, half-life 123 to 139 h, −4.7% to −8.0% at day 29 vs −0.5% on placebo. Phase 2: CT388-103 (obesity) and CT-388-104 (diabetes). Phase 3: ENITH-1 (NCT07351045, ~2,000, three dosing regimens) and ENITH-2 (NCT07351058), sponsor Hoffmann-La Roche.

   Sources

   - Chakravarthy et al. (2026)
   - Roche (phase 2 obesity release) (2026)
   - Roche (phase 2 diabetes release) (2026)

   Updated Nov 2026
4. With BPC-157 Community

   ### Why people add BPC-157 to a GLP-1

   GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.

   The science

   BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside enicepatide or any GLP-1 drug; the pairing comes from community reports.

   Sources

   - Sikiric et al. (2018)

   Updated Nov 2026

### After week 8

1. Day 85–336 RCT

   ### With type 2 diabetes

   In a 48-week trial in type 2 diabetes, the 24 mg dose lowered HbA1c by 2.65 points and weight by about 15.5%. Nine in ten on that dose reached an HbA1c of 6.5% or lower, and few stopped for side effects.

   The science

   CT-388-104 (NCT06628362; 447 adults with type 2 diabetes and overweight or obesity): at 24 mg, HbA1c −2.65% from 8.1% (−4.13% when baseline was above 8.5%); 90% reached ≤6.5% and 62% below 5.7%; weight −15.5% with no plateau; stopping for side effects 2.0% on enicepatide vs 0.0% on placebo (Roche, Sep-22-2026; topline).

   Sources

   - Roche (phase 2 diabetes release) (2026)

   Updated Nov 2026
2. Day 113–336 · 24 mg RCT

   ### The top dose tested

   You're at 24 mg, the highest dose in phase 2. At 48 weeks that group lost about 22.5% more weight than placebo, and nearly half lost at least 20% of their weight. The curve had not flattened by the end.

   The science

   CT388-103 at 24 mg, week 48: placebo-adjusted −22.5% (efficacy estimand) and −18.3% (treatment-regimen estimand), both p < 0.001; 95.7% reached ≥5% loss, 87% ≥10%, 47.8% ≥20% and 26.1% ≥30%; 54% reached a BMI under 30 vs 13% on placebo; 73% of those with prediabetes returned to normal glucose (Roche, Jan-27-2026). Topline and poster; not yet a paper.

   Sources

   - Roche (phase 2 obesity release) (2026)

   Updated Nov 2026
3. Day 337+ Clinical

   ### A long-term medicine, not a course

   Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Enicepatide hasn't been tested in a stopping trial, so this is the pattern of other weight drugs. Continue, taper or stop is a call for you and your clinician.

   The science

   A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). No withdrawal trial of enicepatide has been published.

   Sources

   - West et al. (2026)

   Updated Nov 2026

Day 1 is the day you start it.

Phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405), obesity phase 2 (Roche, Jan-27-2026; ADA 2026 poster; NCT06525935), diabetes phase 2 (Roche, Sep-22-2026; NCT06628362), ENITH records on ClinicalTrials.gov. Investigational.

Moderate evidence

## More on enicepatide

### Dose Guide

- [Enicepatide dose guide](https://pepvault.app/lab/dosage/enicepatide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/enicepatide-10mg)

### Studies

- [Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1](https://pepvault.app/research/enicepatide-chakravarthy-2026)
- [The study on the research page](https://pepvault.app/research#enicepatide)

### Compared with

- [Tirzepatide vs Enicepatide](https://pepvault.app/peptides/compare/tirzepatide-vs-enicepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [GLP-1](https://pepvault.app/glossary/glp-1)

## Mixing and a typical run.

Example numbers

### Reconstitution example

Reconstitute a 10 mg vial of Enicepatide with 2 mL of bacteriostatic water and a 2 mg dose is 40 units on a U-100 syringe, about 5 doses per vial.

- **Vial:** 10 mg
- **Water:** 2 mL
- **Amount:** 2 mg

Draw to **40 units**

0.5 mL insulin syringe · 50 units

[Mix it in the Reconstitution Lab](https://pepvault.app/lab) [Open the calculator](https://pepvault.app/tools/reconstitution-calculator)

### Run notes

- **Cycle:** Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it. Community practice — opinions vary. Not a clinical recommendation.
- **Timing:** Once weekly SubQ, same day each week, in its trials. In the obesity phase 2, the higher-dose groups stepped up from 2 mg through 4, 8, 12, 16 and 20 mg to 24 mg, reaching their top dose within 27 weeks, with slower steps allowed for tolerability; the lowest groups started at 4 mg. These are trial schedules, not an approved regimen.
- **Route:** SubQ injection
- **Stacks:** BPC-157 (GI support)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-next-mixing&mt=8)

<!--/promo-->

## Safety.

### Common side effects

- Nausea
- Constipation
- Diarrhea
- Vomiting

#### Interactions

No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. Roche plans to test it with its amylin drug petrelintide. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

### Safety notes

Enicepatide has no label: it is still in trials. In the 48-week obesity phase 2 trial, most side effects were GI (nausea, constipation, diarrhea, vomiting) and mild to moderate, in line with the incretin class; 5.9% on enicepatide stopped for side effects vs 1.3% on placebo, and serious events were low and not dose-related, with no grade 4 or 5 events. In the diabetes phase 2 trial, 2.0% stopped for side effects vs 0% on placebo. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

## Goes with.

- [BPC-157 GI support](https://pepvault.app/peptides/bpc-157)

## One question at a time.

- [Half-life](https://pepvault.app/peptides/enicepatide/half-life)
- [Side effects](https://pepvault.app/peptides/enicepatide/side-effects)
- [How long it takes to work](https://pepvault.app/peptides/enicepatide/how-long-to-work)
- [Legal status](https://pepvault.app/peptides/enicepatide/legal-status)

## Compared with.

- [Tirzepatide vs Enicepatide](https://pepvault.app/peptides/compare/tirzepatide-vs-enicepatide)

## Mixing charts by vial size.

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/enicepatide-10mg)

## Studies, in plain English.

- [Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1](https://pepvault.app/research/enicepatide-chakravarthy-2026)
- [Every study on Enicepatide](https://pepvault.app/research#enicepatide)

## Questions people ask.

### What is Enicepatide?

A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened.

### How is Enicepatide dosed in research?

The research range for Enicepatide is 4–24 mg, weekly, with a 2 mg starting dose. Studied in research — not a recommendation.

### How long does Enicepatide last?

The half-life of Enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).

### What do people report on Enicepatide?

Commonly reported on Enicepatide: in trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.

### Is Enicepatide safe?

The research basis for Enicepatide is moderate: animal studies + some human data. Common side effects in the library: nausea, constipation, diarrhea and vomiting.

### What does Enicepatide stack with?

Common stacks for Enicepatide: BPC-157 (GI support).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-next-questions&mt=8)

<!--/promo-->

## Research.

The literature

### Search the latest research

[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Enicepatide) [Google Scholar](https://scholar.google.com/scholar?q=Enicepatide)

## Reference.

- **Cadence:** Weekly
- **Half-life:** ~5.5 days ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026)
- **Research basis:** Moderate Animal studies + some human data

## More metabolic & glp-1 peptides

- [Ecnoglutide 0.6–2.4 mg](https://pepvault.app/peptides/ecnoglutide)
- [Efinopegdutide 4–10 mg](https://pepvault.app/peptides/efinopegdutide)
- [5-Amino-1MQ 50–100 mg](https://pepvault.app/peptides/5-amino-1mq)
- [SLU-PP-332 250–1000 mcg](https://pepvault.app/peptides/slu-pp-332)
- [Oxytocin 10–40 IU](https://pepvault.app/peptides/oxytocin)
- [Semaglutide 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Free tools

- [Enicepatide dose guide](https://pepvault.app/lab/dosage/enicepatide)
- [Reconstitution Lab (3D)](https://pepvault.app/lab)
- [Injection guide (3D)](https://pepvault.app/lab/injection)
- [Peptide Sky (3D)](https://pepvault.app/lab/sky)
- [Peptide tier list](https://pepvault.app/lab/tiers)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

<!--promo-->

PepVault for iPhone

## Track enicepatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track enicepatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## More on enicepatide

### Dose Guide

- [Enicepatide dose guide](https://pepvault.app/lab/dosage/enicepatide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/enicepatide-10mg)

### Studies

- [Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1](https://pepvault.app/research/enicepatide-chakravarthy-2026)
- [The study on the research page](https://pepvault.app/research#enicepatide)

### Compared with

- [Tirzepatide vs Enicepatide](https://pepvault.app/peptides/compare/tirzepatide-vs-enicepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [GLP-1](https://pepvault.app/glossary/glp-1)

<!--promo-->

PepVault for iPhone

## Track enicepatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
